Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2026)
Aytu Biopharma (AYTU) reported Asset Writedowns and Impairment of $700000.0 for Q1 2026, up 600.0% year-over-year from $100000.0 in Q1 2025, and down 12.5% quarter-over-quarter from $800000.0 in Q4 2025.
Aytu Biopharma (AYTU) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 7 years of Asset Writedowns and Impairment data on file, last reported at $700000.0 in Q1 2026.
- Asset Writedowns and Impairment for Q1 2026 came in at $700000.0, up 600.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (up 41.49% YoY), and the FY2025 annual result was $325000.0, down 72.67% from the prior year.
- Asset Writedowns and Impairment eased to $700000.0 in Q1 2026 per AYTU's latest filing, from $800000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $45.2 million in Q1 2022 and troughed at $68000.0 in Q3 2024.
- A 5-year average of $3.9 million and a median of $121000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2023 and 2025: Asset Writedowns and Impairment sank 99.78% in 2023, then soared 700.0% in 2025.
- A 5-year view of Asset Writedowns and Impairment shows it stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then changed by 0.0% to $100000.0 in 2024, then soared by 700.0% to $800000.0 in 2025, then fell by 12.5% to $700000.0 in 2026.
- Business Quant data shows AYTU's Asset Writedowns and Impairment at $700000.0 in Q1 2026, $800000.0 in Q4 2025, and $278000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 700,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Dec 31, 2025 | 800,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Sep 30, 2025 | 278,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |